<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="42262"><DrugName>zoptarelin doxorubicin (intravenous, cancer), AEterna Zentaris/ Sinopharm/ Orient EuroPharma</DrugName><DrugNamesKey><Name id="43074578">Zoptrex</Name><Name id="42983953">zoptarelin doxorubicin</Name><Name id="43103009">zoptarelin doxorubicin acetate</Name></DrugNamesKey><DrugSynonyms><Name><Value>AN-152</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>doxorubicin-LHRH-conjugate, Tulane University/Zentaris</Value></Name><Name><Value>ZEN-008</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>doxorubicin-LHRH-conjugate (intravenous, cancer), AEterna Zentaris</Value></Name><Name><Value>zoptarelin doxorubicin</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>AEZS-108</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>zoptarelin doxorubicin (intravenous, cancer), AEterna Zentaris</Value></Name><Name><Value>zoptarelin doxorubicin (intravenous, cancer), AEterna Zentaris/ Sinopharm/ Orient EuroPharma</Value></Name><Name><Value>Zoptrex</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>zoptarelin doxorubicin acetate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>139570-93-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>23214-92-8</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1928750-34-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22292">Tulane University</CompanyOriginator><CompaniesSecondary><Company id="1075034">Sinopharma A-Think Pharmaceutical Co Ltd</Company><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><Company id="22292">Tulane University</Company><Company id="22711">AEterna Zentaris Inc</Company><Company id="26232">Rafa Laboratories Ltd</Company><Company id="29069">Zentaris GmbH</Company><Company id="DOL1000087">Orient Europharma</Company></CompaniesSecondary><CrossReferences><SourceEntity id="42262" type="Drug"><TargetEntity id="253383" type="siDrug">Zoptarelin doxorubicin</TargetEntity></SourceEntity><SourceEntity id="1075034" type="Company"><TargetEntity id="5000465081" type="organizationId">Sinopharm A-Think Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1157003" type="Company"><TargetEntity id="5056200653" type="organizationId">Specialised Therapeutics Asia Pte Ltd</TargetEntity></SourceEntity><SourceEntity id="22292" type="Company"><TargetEntity id="5000726152" type="organizationId">Tulane University</TargetEntity></SourceEntity><SourceEntity id="22711" type="Company"><TargetEntity id="4295862603" type="organizationId">Aeterna Zentaris Inc</TargetEntity></SourceEntity><SourceEntity id="26232" type="Company"><TargetEntity id="4297243567" type="organizationId">Rafa Laboratories Ltd</TargetEntity></SourceEntity><SourceEntity id="29069" type="Company"><TargetEntity id="5000760039" type="organizationId">Aeterna Zentaris GmbH</TargetEntity></SourceEntity><SourceEntity id="DOL1000087" type="Company"><TargetEntity id="4295892315" type="organizationId">Orient Europharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1705" type="ciIndication"><TargetEntity id="10014733" type="MEDDRA"></TargetEntity><TargetEntity id="D016889" type="MeSH"></TargetEntity><TargetEntity id="-49801714" type="omicsDisease"></TargetEntity><TargetEntity id="597" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1771" type="ciIndication"><TargetEntity id="10044412" type="MEDDRA"></TargetEntity><TargetEntity id="D002295" type="MeSH"></TargetEntity><TargetEntity id="-807613677" type="omicsDisease"></TargetEntity><TargetEntity id="677" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="42" type="ciIndication"><TargetEntity id="10005056" type="MEDDRA"></TargetEntity><TargetEntity id="D001749" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="750" type="Action"><TargetEntity id="1405" type="Mechanism">DNA-Intercalating Drugs</TargetEntity></SourceEntity><SourceEntity id="3277" type="Action"><TargetEntity id="1633" type="Mechanism">Gonadotropin-Releasing Factor Hormone Receptor (GnRH; LHRH) Ligands</TargetEntity></SourceEntity><SourceEntity id="PTGT-00881" type="ciTarget"><TargetEntity id="14970030727983" type="siTarget">Gonadotropin-releasing hormone receptor</TargetEntity><TargetEntity id="2775" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1705">Endometrioid carcinoma</Indication><Indication id="1771">Transitional cell carcinoma</Indication><Indication id="276">Prostate tumor</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="42">Bladder tumor</Indication><Indication id="49">Breast tumor</Indication><Indication id="651">Cancer</Indication><Indication id="799">Ovary tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3277">GNRH receptor modulator</Action></ActionsPrimary><ActionsSecondary><Action id="140">DNA synthesis inhibitor</Action><Action id="1545">Anticancer</Action><Action id="750">DNA intercalator</Action></ActionsSecondary><Technologies><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="207">Protein conjugated</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2019-04-25T04:05:00.000Z</LastModificationDate><ChangeDateLast>2019-04-25T00:00:00.000Z</ChangeDateLast><AddedDate>2002-10-25T15:24:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22711" linkType="Company"&gt;AEterna Zentaris&lt;/ulink&gt; (formerly &lt;ulink linkID="29069" linkType="Company"&gt;Zentaris&lt;/ulink&gt;), under license from &lt;ulink linkID="22292" linkType="Company"&gt;Tulane University&lt;/ulink&gt;, was developing zoptarelin doxorubicin (AEZS-108; AN-152, ZEN-008, Zoptrex), a conjugate of doxorubicin (DOX) and [D-Lys(6)]LHRH (luteinizing hormone releasing hormone), for the potential iv treatment of various cancers [&lt;ulink linkID="466729" linkType="Reference"&gt;466729&lt;/ulink&gt;], [&lt;ulink linkID="467641" linkType="Reference"&gt;467641&lt;/ulink&gt;], [&lt;ulink linkID="1712301" linkType="Reference"&gt;1712301&lt;/ulink&gt;]. In May 2013, a phase III trial for endometrial cancer was initiated in the US [&lt;ulink linkID="1401810" linkType="Reference"&gt;1401810&lt;/ulink&gt;]. In July 2013,  the trial was initiated in Israel [&lt;ulink linkID="1401810" linkType="Reference"&gt;1401810&lt;/ulink&gt;], [&lt;ulink linkID="1459061" linkType="Reference"&gt;1459061&lt;/ulink&gt;]. In December 2007, a phase II trial in gynecological tumors was initiated [&lt;ulink linkID="862616" linkType="Reference"&gt;862616&lt;/ulink&gt;]; in October 2009,  data for ovarian cancer  were reported [&lt;ulink linkID="1053559" linkType="Reference"&gt;1053559&lt;/ulink&gt;].    In August 2011, a parallel scientific advice process was initiated with the EMA to have the pivotal program   for endometrial cancer  [&lt;ulink linkID="1214186" linkType="Reference"&gt;1214186&lt;/ulink&gt;].  By January 2012, phase II  trial initiated for prostate cancer [&lt;ulink linkID="1252656" linkType="Reference"&gt;1252656&lt;/ulink&gt;]. In December 2012, the drug was in phase II development for breast cancer [&lt;ulink linkID="1353108" linkType="Reference"&gt;1353108&lt;/ulink&gt;]; in February 2013, the first patient was treated in a phase II study [&lt;ulink linkID="1384879" linkType="Reference"&gt;1384879&lt;/ulink&gt;], [&lt;ulink linkID="1385088" linkType="Reference"&gt;1385088&lt;/ulink&gt;]. In December 2014, phase III trial in endometrial cancer and phase II trials in ovarian and prostate cancers were ongoing [&lt;ulink linkID="1616721" linkType="Reference"&gt;1616721&lt;/ulink&gt;]; in November 2016, this was still the case [&lt;ulink linkID="1876073" linkType="Reference"&gt;1876073&lt;/ulink&gt;].  In March 2016, the company was planning to file the NDA for Zoptrex in the second half of 2017. In November 2016, the company was seeking to outlicense the drug [&lt;ulink linkID="1886539" linkType="Reference"&gt;1886539&lt;/ulink&gt;],  [&lt;ulink linkID="1886529" linkType="Reference"&gt;1886529&lt;/ulink&gt;]. However, in May 2017, the company anticipated to not conduct clinical trials  with respect to any  indications following negative data from ZoptEC trial, and the company's focus shifted to further development of &lt;ulink linkID="40909" linkType="Drug"&gt;Macrilen&lt;/ulink&gt; [&lt;ulink linkID="1922888" linkType="Reference"&gt;1922888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Licensee &lt;ulink linkID="1075034" linkType="Company"&gt;Sinopharma A-Think&lt;/ulink&gt; was  investigating the treatment for endometrial cancer [&lt;ulink linkID="1616861" linkType="Reference"&gt;1616861&lt;/ulink&gt;]. In March 2016, Sinopharma A-Think was on track to submit a Clinical Trial Application to the SFDA in summer 2016 and expected to initiate clinical trials 'later that year' [&lt;ulink linkID="1739299" linkType="Reference"&gt;1739299&lt;/ulink&gt;]. In June 2016, Sinopharma A-Think submitted an IND application for Zoptrex  to the SFDA and expected to initiate clinical trials  during the first half of 2017 [&lt;ulink linkID="1773082" linkType="Reference"&gt;1773082&lt;/ulink&gt;]. However, in May 2017, further development of the drug was discontinued by AEterna  [&lt;ulink linkID="1922888" linkType="Reference"&gt;1922888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Licensee &lt;ulink linkID="DOL1000087" linkType="Company"&gt;Orient EuroPharma&lt;/ulink&gt; was  investigating the agent for endometrial cancer [&lt;ulink linkID="1777630" linkType="Reference"&gt;1777630&lt;/ulink&gt;]. However, in May 2017, further development of the drug was discontinued by AEterna  [&lt;ulink linkID="1922888" linkType="Reference"&gt;1922888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Licensee  &lt;ulink linkID="1157003" linkType="Company"&gt;Specialised Therapeutics&lt;/ulink&gt; was investigating the drug in Australia and New Zeland, for the potential treatment of cancer [&lt;ulink linkID="1806529" linkType="Reference"&gt;1806529&lt;/ulink&gt;]. However, in May 2017, further development of the drug was discontinued by AEterna  [&lt;ulink linkID="1922888" linkType="Reference"&gt;1922888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;AEterna Zentaris was previously developing the drug for the potential treatment of bladder tumor. By December 2010, phase I/II trials for bladder  cancer had begun [&lt;ulink linkID="1156094" linkType="Reference"&gt;1156094&lt;/ulink&gt;]; in August 2011,  the  trials  were ongoing [&lt;ulink linkID="1214186" linkType="Reference"&gt;1214186&lt;/ulink&gt;]. However, by June 2015, no development had been reported for this indication.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In March 2016, the company was planning to file the NDA for Zoptrex in the second half of 2017 [&lt;ulink linkID="1886539" linkType="Reference"&gt;1886539&lt;/ulink&gt;]. In March 2017, a pre-NDA meeting with FDA was held on January 31, 2017 [&lt;ulink linkID="1908998" linkType="Reference"&gt;1908998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, the FDA granted zoptarelin doxorubicin   Orphan Drug status for ovarian cancer [&lt;ulink linkID="1096462" linkType="Reference"&gt;1096462&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2010, the  EMA's COMP adopted a  positive opinion   on   granting the drug Orphan status to zoptarelin doxorubicin      for ovarian cancer [&lt;ulink linkID="1100071" linkType="Reference"&gt;1100071&lt;/ulink&gt;]. By September 2011, EMA had granted an Orphan Drug status to AEZS-108 for ovarian cancer [&lt;ulink linkID="1222493" linkType="Reference"&gt;1222493&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In October 2011, the FDA  approved an IND for a phase II trial in chemotherapy refractory triple-negative  luteinizing hormone-releasing hormone receptor-positive metastatic breast cancer. The open-label, randomized, two-arm, multicenter phase II study in up to 74 patients would have a primary  endpoint of median time to progression, with secondary endpoints of overall response-rate, overall survival, quality of life and toxicity [&lt;ulink linkID="1233230" linkType="Reference"&gt;1233230&lt;/ulink&gt;]. In December 2012, the drug was in phase II development for breast cancer [&lt;ulink linkID="1353108" linkType="Reference"&gt;1353108&lt;/ulink&gt;]. In February 2013, the first patient was treated in the phase II study (&lt;ulink linkID="93109" linkType="Protocol"&gt;NCT01698281&lt;/ulink&gt;, AEZS-108-049). At that time, the study was expected to complete in October 2014 [&lt;ulink linkID="1384879" linkType="Reference"&gt;1384879&lt;/ulink&gt;], [&lt;ulink linkID="1385088" linkType="Reference"&gt;1385088&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, AEterna initiated a German phase I dose-ranging study of zoptarelin doxorubicin   in patients with LHRH receptor positive breast cancer [&lt;ulink linkID="580301" linkType="Reference"&gt;580301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt; By December 2010, phase I/II trials prostate cancer had begun [&lt;ulink linkID="1156094" linkType="Reference"&gt;1156094&lt;/ulink&gt;]. In August 2010, the &lt;ulink linkID="20518" linkType="Company"&gt;National Institutes of Health&lt;/ulink&gt; (NIH) awarded funding to the &lt;ulink linkID="1055634" linkType="Company"&gt;Norris Comprehensive Cancer Center&lt;/ulink&gt; of the University of Southern California to conduct a phase I/II trial of the drug in refractory prostate cancer. The study in castration- and taxane-resistant prostate cancer would enroll up to 55 patients. The first phase would be an abbreviated dose-escalation followed by a single-arm [&lt;ulink linkID="1121609" linkType="Reference"&gt;1121609&lt;/ulink&gt;]. In November 2010, enrollment of patients began [&lt;ulink linkID="1225793" linkType="Reference"&gt;1225793&lt;/ulink&gt;]. By December 2010, the first patients had been dosed [&lt;ulink linkID="1156094" linkType="Reference"&gt;1156094&lt;/ulink&gt;]. In August 2011,  the phase I/II trials for prostate cancer were ongoing [&lt;ulink linkID="1214186" linkType="Reference"&gt;1214186&lt;/ulink&gt;]. In July 2011, the open label, single group assignment trial (&lt;ulink linkID="72234" linkType="Protocol"&gt;NCT01240629&lt;/ulink&gt;, 4P-09-9, NCI-2009-01418) was expected to complete in April 2013, with estimated enrollment as  55 patients [&lt;ulink linkID="1260299" linkType="Reference"&gt;1260299&lt;/ulink&gt;]. In September 2011, interim data from 10 out of 12 patients from the phase I portion of the trial were presented at the European Society of Medical Oncology   Congress  in Stockholm, Sweden. The drug was found to be well tolerated at all doses.  Significant therapeutic anti-tumor activity, including maximal prostate  specific antigen regression,  was observed at low doses of 160 and 210 mg/m2 in five patients. In correlative studies, internalization of zoptarelin doxorubicin  was observed in circulating tumor cells (CTC)   isolated from treated patients. Stable disease was achieved by all three evaluable patients with measurable disease. If the toxicity assessment in the final tier of phase I was acceptable, a phase II extension of this study would be planned [&lt;ulink linkID="1225536" linkType="Reference"&gt;1225536&lt;/ulink&gt;], [&lt;ulink linkID="1225793" linkType="Reference"&gt;1225793&lt;/ulink&gt;], [&lt;ulink linkID="1223333" linkType="Reference"&gt;1223333&lt;/ulink&gt;]. In September 2011, interim data from the phase I portion of the phase I/II  prostate cancer trial were presented [&lt;ulink linkID="1225536" linkType="Reference"&gt;1225536&lt;/ulink&gt;], [&lt;ulink linkID="1225793" linkType="Reference"&gt;1225793&lt;/ulink&gt;]. By January 2012, phase II studies had begun [&lt;ulink linkID="1252656" linkType="Reference"&gt;1252656&lt;/ulink&gt;]. Later that month, updated interim results  from the phase I trial were to be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium(GCS) in San Francisco, CA  in February 2012  [&lt;ulink linkID="1257838" linkType="Reference"&gt;1257838&lt;/ulink&gt;]. In February 2012,   data from 13 out of  18 planned patients  were presented at the ASCO-GU Symposium in San Francisco, CA,     showing that the drug  was  well tolerated at 160, 210  and  267 mg/m2, especially in the  heavily  pretreated older patient group. Even though the drug was administered in low doses in the first cohorts, significant evidence of antitumor activity was demonstrated. Due to continued benefit,   a patient received 8 cycles at 210  mg/m2.  Stable disease was achieved by 4 of the 5 evaluable patients with  measurable disease. Decrease in PSA   was  found in 6 patients, at the submission time. A total of 6 of 13  (46%)   patients had  received at least five cycles of therapy, with no    disease progression evidence at 12 weeks. In the correlative studies, the feasibility of capturing CTCs to monitor drug internalization and the drug uptake into the targeted tumor was demonstrated; at that time, following the   treatment completion of 3 additional patients at dose level of 210 mg/m2, the study was expected to   extend into the phase II portion [&lt;ulink linkID="1259920" linkType="Reference"&gt;1259920&lt;/ulink&gt;], [&lt;ulink linkID="1260237" linkType="Reference"&gt;1260237&lt;/ulink&gt;], [&lt;ulink linkID="1261377" linkType="Reference"&gt;1261377&lt;/ulink&gt;]. In June 2012, further data from a single-arm, dose-escalation, phase I study were presented at the 48th ASCO meeting at Chicago, IL.   AEZS-108 was generally well tolerated. At that time, the study was ongoing, and the phase II part of the study was expected to begin once the MTD was established [&lt;ulink linkID="1296446" linkType="Reference"&gt;1296446&lt;/ulink&gt;]. In November 2012, the phase II section of the study was initiated. The phase II section was expected to include up to 37 patients [&lt;ulink linkID="1339807" linkType="Reference"&gt;1339807&lt;/ulink&gt;]. In June 2013, further phase I data from 18 patients were presented at the 49th ASCO meeting in Chicago, IL. AEZS-108 was well tolerated and the 210 mg/m2 dose was determined as the MTD and recommended phase II dose; at that time,  final phase I data were presented [&lt;ulink linkID="1425227" linkType="Reference"&gt;1425227&lt;/ulink&gt;], [&lt;ulink linkID="1426984" linkType="Reference"&gt;1426984&lt;/ulink&gt;]. In June 2013, the phase II portion of the study was ongoing [&lt;ulink linkID="1425227" linkType="Reference"&gt;1425227&lt;/ulink&gt;], [&lt;ulink linkID="1426984" linkType="Reference"&gt;1426984&lt;/ulink&gt;], [&lt;ulink linkID="1432369" linkType="Reference"&gt;1432369&lt;/ulink&gt;]. In October 2014, phase I data were published. In the study, three patients showed PSA response, and  an additional 10 patients maintained PSA stable disease. Of the 10   patients evaluable by RECIST criteria, 9 had stable disease. At that time, single-arm, Simon Optimum design, phase II study in prostate cancer patients administered with 210 mg/m2 of the drug, was ongoing [&lt;ulink linkID="1623316" linkType="Reference"&gt;1623316&lt;/ulink&gt;], [&lt;ulink linkID="1623241" linkType="Reference"&gt;1623241&lt;/ulink&gt;]. In September 2015, clinical data were presented from phase II portion of the study in 25 patients at the 2015 European Cancer Congress in Vienna, Austria. Clinical benefit (primary endpoint) and stable disease were noted in 11 and 13 patients, respectively. Median overall survival and progression free survival  were 6 and 4.4 months, respectively [&lt;ulink linkID="1698354" linkType="Reference"&gt;1698354&lt;/ulink&gt;], [&lt;ulink linkID="1698400" linkType="Reference"&gt;1698400&lt;/ulink&gt;]. In February 2017, further data from the trial were expected to be presented at the upcoming 2017 Genitourinary Cancers Symposium [&lt;ulink linkID="1900394" linkType="Reference"&gt;1900394&lt;/ulink&gt;]. Further data were presented at the same conference. Clinical benefit and &amp;gt;/= 12 weeks progression-free survival (PFS; primary endpoint) was achieved by 13 and 15 patients, respectively. Median PFS, overall survival (secondary endpoint) and follow-up was 3.8, 6 and 16.1 months, respectively. Following treatment six, three and two patients had decreased, no change and increase count of circulating tumor cells for baseline, respectively [&lt;ulink linkID="1904673" linkType="Reference"&gt;1904673&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bladder cancer&lt;/subtitle&gt;In May 2010, the FDA approved an IND application for LHRH receptor positive bladder cancer. At that time, the company planned to initiate a 64-patient, phase II trial for bladder cancer in the second half of 2010 [&lt;ulink linkID="1098738" linkType="Reference"&gt;1098738&lt;/ulink&gt;]. By December 2010, patient screening in a phase I/II trial had begun  [&lt;ulink linkID="1156094" linkType="Reference"&gt;1156094&lt;/ulink&gt;]. By January 2012, phase II studies had begun [&lt;ulink linkID="1252656" linkType="Reference"&gt;1252656&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian and endometrial cancer&lt;/subtitle&gt;In November 2011, the company planned to initiate a phase III trial for endometrial cancer [&lt;ulink linkID="1238368" linkType="Reference"&gt;1238368&lt;/ulink&gt;]. In August 2012, an SPA was to be filed for the phase  III trial in September 2012 [&lt;ulink linkID="1315578" linkType="Reference"&gt;1315578&lt;/ulink&gt;].   In the third quarter of 2012, an SPA was filed and  the phase III endometrial cancer trial was expected to start in  the first quarter of 2013 [&lt;ulink linkID="1340357" linkType="Reference"&gt;1340357&lt;/ulink&gt;]. In December 2012, the company reached an agreement with the US FDA on the  SPA for the randomized, open-label, multicenter registration trial (&lt;ulink linkID="104538" linkType="Protocol"&gt;NCT01767155&lt;/ulink&gt;; AEZS -108-050; EudraCT No: 2012-005546-38). The study would compare AEZS-108 with doxorubicin, and would be conducted in North America, Europe and Israel, in patients (expected n = 500) with locally-advanced, recurrent or metastatic endometrial cancer. The trial was expected to begin in March 2013 and complete in January 2016 [&lt;ulink linkID="1353108" linkType="Reference"&gt;1353108&lt;/ulink&gt;], [&lt;ulink linkID="1401810" linkType="Reference"&gt;1401810&lt;/ulink&gt;], [&lt;ulink linkID="1402314" linkType="Reference"&gt;1402314&lt;/ulink&gt;], [&lt;ulink linkID="1674289" linkType="Reference"&gt;1674289&lt;/ulink&gt;]. In May 2013, it was reported at BIT's World Cancer Congress in Xi'an, China, that this trial would start soon [&lt;ulink linkID="1431478" linkType="Reference"&gt;1431478&lt;/ulink&gt;]; later that month, the trial was initiated in the US  [&lt;ulink linkID="1401810" linkType="Reference"&gt;1401810&lt;/ulink&gt;]. In July 2013,  enrollment was initiated in the US and Israel [&lt;ulink linkID="1401810" linkType="Reference"&gt;1401810&lt;/ulink&gt;], [&lt;ulink linkID="1459061" linkType="Reference"&gt;1459061&lt;/ulink&gt;]. In February 2014, the recruitment was ongoing at multiple sites in North America, Europe and Israel [&lt;ulink linkID="1521166" linkType="Reference"&gt;1521166&lt;/ulink&gt;]. In May 2014, the ZoptEC trial had enrolled more than 140 patients and first interim analysis was expected in the first half of 2015 [&lt;ulink linkID="1554798" linkType="Reference"&gt;1554798&lt;/ulink&gt;]; by August 2014, 230 patients had been recruited [&lt;ulink linkID="1583895" linkType="Reference"&gt;1583895&lt;/ulink&gt;]. By Novemebr 2014, 320 patients had been recruited [&lt;ulink linkID="1614364" linkType="Reference"&gt;1614364&lt;/ulink&gt;]. By March 2015, 400 patients had been enrolled, and at that time, recruitment was expected to complete by the end of 2015 [&lt;ulink linkID="1642606" linkType="Reference"&gt;1642606&lt;/ulink&gt;]; in April 2015, independent data safety monitoring board (DSMB) completed first interim futility analysis and recommended to continue the trial as planned [&lt;ulink linkID="1654526" linkType="Reference"&gt;1654526&lt;/ulink&gt;]. By May 2015, 465 patients had been enrolled, and at that time, second interim analysis data were expected by the end of 2015 [&lt;ulink linkID="1657815" linkType="Reference"&gt;1657815&lt;/ulink&gt;]. In June 2015, enrollment was completed and at that time, the second interim analysis was expected by the fourth quarter of 2015 at approximately 192 events, with the final analysis planned at an anticipated 384 events. The trial was expected to be completed by the end of 2016  [&lt;ulink linkID="1674289" linkType="Reference"&gt;1674289&lt;/ulink&gt;]. In August 2015, the DSMB was expected to complete the pre-specified second interim analysis in early October 2015 and report the results 'soon thereafter' [&lt;ulink linkID="1685377" linkType="Reference"&gt;1685377&lt;/ulink&gt;]. In October 2015, the DSMB completed second interim futility analysis and recommended to continue the trial [&lt;ulink linkID="1702747" linkType="Reference"&gt;1702747&lt;/ulink&gt;].  In December 2015,  the company expected   to complete the trial during the third quarter of 2016 and   report topline data  'shortly thereafter' [&lt;ulink linkID="1719632" linkType="Reference"&gt;1719632&lt;/ulink&gt;]. In January 2016, the trial was fully-enrolled and was expected to conclude in the second half of 2016 [&lt;ulink linkID="1727250" linkType="Reference"&gt;1727250&lt;/ulink&gt;]. In March 2016, the company was planning to commence the trial in China in the second half of 2016 [&lt;ulink linkID="1747045" linkType="Reference"&gt;1747045&lt;/ulink&gt;]. In September 2016, the company was  planning to complete the trial towards the end of 2016 and report data early in 2017 [&lt;ulink linkID="1799041" linkType="Reference"&gt;1799041&lt;/ulink&gt;], [&lt;ulink linkID="1886529" linkType="Reference"&gt;1886529&lt;/ulink&gt;]. In January 2017, the trial was completed and 384th death occured. Patients were centrally randomized in a 1:1 ratio and dosed with either Zoptrex (267 mg/m2) or doxorubicin (60 mg/m2) intravenously, every three weeks and for up to nine cycles. At that time, top-line data were expected in April 2017 [&lt;ulink linkID="1896399" linkType="Reference"&gt;1896399&lt;/ulink&gt;]. In May 2017, data were reported. The study did not meet the primary endpoint of demonstrating a statistically significant increase in the median period of overall survival of patients treated with Zoptrex compared to doxorubicin. The median overall survival period was 10.9 months for Zoptrex-treated patients compared to 10.8 months for doxorubicin-treated patients which wasnt significant, clinically meaningful response. No meaningful difference was seen between the two arms with respect to safety. The data were not supportive to pursue regulatory approval [&lt;ulink linkID="1922888" linkType="Reference"&gt;1922888&lt;/ulink&gt;]. In June 2018, further clinical data were presented at the 54th ASCO Annual Meeting in Chicago, IL. In the intent-to treat population in zoptarelin versus doxorubicin arms (n = 511), overall response rate was 12.5 versus 14.1%; Clinical benefit rate (RECIST 1.1) was 54 versus 52%; duration of response was 6.8 versus 9 months, respectively. In AEZS-108 versus doxorubicin arms, the median PFS was 4.7 versus 4.7 months. There were no important trends, nor differences in EORTC QLQ-C30 questionnaire by treatment group. The common grade &amp;gt;/= 3 adverse events reported were neutropenia, leukopenia and anemia  [&lt;ulink linkID="2039817" linkType="Reference"&gt;2039817&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, a pivotal trial for endometrial cancer was planned  [&lt;ulink linkID="1156094" linkType="Reference"&gt;1156094&lt;/ulink&gt;]. In August 2011, parallel scientific advice process was initiated with the FDA and  EMA to have the pivotal program   for endometrial cancer defined by the end of 2011 [&lt;ulink linkID="1214186" linkType="Reference"&gt;1214186&lt;/ulink&gt;]. In January 2012, the pivotal trial was expected to be initiated in the first half of 2012 [&lt;ulink linkID="1252656" linkType="Reference"&gt;1252656&lt;/ulink&gt;]. In July 2012, the company intended to initiate the trial by the end of 2012 [&lt;ulink linkID="1311231" linkType="Reference"&gt;1311231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, a non-randomized, open-label, uncontrolled, single-group-assignment, phase II trial (&lt;ulink linkID="34017" linkType="Protocol"&gt;NCT00569257&lt;/ulink&gt;; AEZS-108-040, AGO-GYN 5, EudraCT No. 2007-002663-26) was initiated in subjects (expected n = 82) with ovarian or endometrial cancer in Germany and Bulgaria. The subjects were to receive zoptarelin doxorubicin as an iv infusion at a dose of 267 mg/m2 every 3 weeks for up to 6 treatment cycles. The primary endpoint was tumor response as per RECIST or GCIG criteria. At that time, the study was scheduled to complete in December 2009 [&lt;ulink linkID="862616" linkType="Reference"&gt;862616&lt;/ulink&gt;]. In February 2008, the company reported that the first patients enrolled in this trial had begun dosing [&lt;ulink linkID="875951" linkType="Reference"&gt;875951&lt;/ulink&gt;]. In October 2008, the company started  the second stage of the trial in ovarian cancer after two partial responses had been achieved by patients [&lt;ulink linkID="948183" linkType="Reference"&gt;948183&lt;/ulink&gt;]. In November 2008, the company also started the second stage of the trial in endometrial cancer after one complete response and two partial responses had been achieved by patients [&lt;ulink linkID="958672" linkType="Reference"&gt;958672&lt;/ulink&gt;]. In October 2009, positive data from the phase II  trial of  zoptarelin doxorubicin  in patients with platinum-resistant and taxane-pretreated ovarian cancer were reported. Preliminary results showed that zoptarelin doxorubicin  had met the primary endpoint with 5 or more responders in 41 evaluable patients. Further analysis, including efficacy data from post-treatment follow-up was to be presented at forthcoming scientific conferences. Secondary endpoints were time-to-progression (TTP), overall survival (OS), toxicity and safety [&lt;ulink linkID="1053559" linkType="Reference"&gt;1053559&lt;/ulink&gt;]. By March 2010, the trial had met its primary endpoint in endometrial cancer of five or more responders [&lt;ulink linkID="1085080" linkType="Reference"&gt;1085080&lt;/ulink&gt;]. In May 2010, final results from the trial were expected later that year [&lt;ulink linkID="1096462" linkType="Reference"&gt;1096462&lt;/ulink&gt;]. By August 2010, positive final results for ovarian cancer had been disclosed and those for endometrial cancer were expected by year-end [&lt;ulink linkID="1121609" linkType="Reference"&gt;1121609&lt;/ulink&gt;]. In June 2010, clinical data were presented at the 46th ASCO meeting in Chicago, IL. In ovarian cancer patients, a partial response was seen in five patients and stable disease for &amp;gt; 12 weeks was seen in 14 patients [&lt;ulink linkID="1105028" linkType="Reference"&gt;1105028&lt;/ulink&gt;]. In September 2011, positive final phase II safety and efficacy data for endometrial cancer were presented at the 17th International Meeting of the European Society of Gynaecological Oncology meeting in Milan, Italy. Data demonstrated that zoptarelin doxorubicin   at 267 mg/m2 dosage was well tolerated and active in 43 patients. The trial met its primary endpoint. The objective response rate was 31% compared to those of single agent platinum or taxane treatment with patients pretreated with platinum/taxane combination. Disease stabilization and clinical benefit rates were found to be 44 and 74%, respectively. Median TTP and OS were 7 and 13.7 months, respectively. The OS of the drug as a single agent was observed to be similar to that of modern triple combination chemotherapy, with lower toxicity [&lt;ulink linkID="1222758" linkType="Reference"&gt;1222758&lt;/ulink&gt;], [&lt;ulink linkID="1222493" linkType="Reference"&gt;1222493&lt;/ulink&gt;]. In February 2014, similar data were published [&lt;ulink linkID="1521456" linkType="Reference"&gt;1521456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I data&lt;/subtitle&gt;In June 2006, results from a phase I trial involving patients with gynecological and breast cancers w	ere reported. Of eight patients given AEZS-108 by iv infusion, one had stable disease and none experienced dose-limiting toxicities.  The agent was well-tolerated, with one patient having grade 2 leukocytopenia at the 160 mg/m2 dose  [&lt;ulink linkID="671677" linkType="Reference"&gt;671677&lt;/ulink&gt;]. In November 2006, further phase I data were reported. The European, open-label, multicenter, dose-escalation, safety and pharmacokinetic study included 17 patients with breast, endometrial and ovarian cancers with proven LHRH receptor status. Zoptarelin doxorubicin  was administered as an iv infusion over 2 h at 10, 20, 40, 80, 160 and 267 mg/m2. Patients received at least two treatment courses, 21 days apart. Zoptarelin doxorubicin  was safe and effective in patients with gynecological and breast cancers, and had an MTD of 267 mg/m2. At the MTD there were cases of CTC grade 4 leucocytopenia/neutropenia in two out of six patients. Pharmacokinetic analyses showed that there were dose-dependent plasma levels of zoptarelin doxorubicin   with only a 10% to 30% release of doxorubicin. One complete response was seen, which would be confirmed by CT scan. Two of six patients had stable disease at a dose of 160 mg/m2. At the MTD, one patient had a partial response and three had stable disease out of a group of seven patients [&lt;ulink linkID="745696" linkType="Reference"&gt;745696&lt;/ulink&gt;]. Similar data were presented at the 43rd ASCO meeting in Chicago, IL in June 2007. It was also disclosed that phase II studies were being prepared [&lt;ulink linkID="797116" linkType="Reference"&gt;797116&lt;/ulink&gt;], [&lt;ulink linkID="801445" linkType="Reference"&gt;801445&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2002, Zentaris anticipated zoptarelin doxorubicin   to enter phase I/II trials in early 2003 [&lt;ulink linkID="466729" linkType="reference"&gt;466729&lt;/ulink&gt;], [&lt;ulink linkID="467641" linkType="reference"&gt;467641&lt;/ulink&gt;].  In January 2005, AEterna initiated a phase I dose-ranging study of zoptarelin doxorubicin in patients with luteinizing hormone releasing hormone (LHRH) receptor positive ovarian, endometrial or breast cancer.  The study, to be conducted in Germany, would evaluate the safety, maximum tolerated dose, dose-limiting toxicity and pharmacokinetics of iv zoptarelin doxorubicin   [&lt;ulink linkID="580301" linkType="Reference"&gt;580301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Transitional cell carcinoma&lt;/subtitle&gt;In May 2014, data from a open-label, dose-escalation phase I study (&lt;ulink linkID="71952" linkType="Protocol"&gt;NCT01234519&lt;/ulink&gt;) performed in 13 advanced unresectable or metastatic urothelial carcinoma patients were presented at the 50th ASCO meeting in Chicago, IL. The MTD was determined to be 210 mg/m2 dose level. Overall, one patient achieved durable partial response and three had stable disease [&lt;ulink linkID="1570261" linkType="Reference"&gt;1570261&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2012, preclinical data were presented at the Annual Meeting of the American Urological Association, in Atlanta, GA.In xenograft mouse models of bladder cancer, a significant decrease in tumor volume and mass was observed following trreatment with zoptarelin doxorubicin in all four models tested. In contrast to doxorubicin treatment, no multidrug-resistance mechanims were induced by zoptarelin doxorubicin, which also resulted in a stronger apoptotic effect than doxorubicin in two of the three cell lines tested [&lt;ulink linkID="1286886" linkType="Reference"&gt;1286886&lt;/ulink&gt;], [&lt;ulink linkID="1311377" linkType="Reference"&gt;1311377&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, preclinical data were presented at the 18th EORTC-NCI-AACR meeting in Prague, Czech Republic. Zoptarelin doxorubicin   was active in endometrial cancer models; growth was inhibited by 54.2%, while treatment with doxorubicin inhibited growth by 23.4%. White blood cell count was significantly reduced by doxorubicin after 8 days, but not by AEZS-108. No respiratory or cardiovascular signals were seen in dogs [&lt;ulink linkID="742642" linkType="Reference"&gt;742642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 2002, nude mice bearing human ovarian cancer xenografts were administered zoptarelin doxorubicin   or doxorubicin or the LHRH peptide mixed with doxorubicin. AEZS-108 treatment at 20 nmol/g reduced tumor size significantly and was much less toxic than the equivalent dose of doxorubicin. Zoptarelin doxorubicin  treatment reduced expression of EGF and LHRH receptors on tumors [&lt;ulink linkID="467954" linkType="reference"&gt;467954&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2001, preclinical data were published. In mice bearing human endometrial and ovarian cancer xenografts, zoptarelin doxorubicin  at 35 nmol/g or 15 nmol/g reduced tumor volume and was less toxic than doxorubicin [&lt;ulink linkID="467880" linkType="reference"&gt;467880&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1999, advanced hormone-independent mouse mammary tumors were treated with &lt;ulink linkID="15419" linkType="Drug"&gt;AN-207&lt;/ulink&gt; or zoptarelin doxorubicin . AN-207 was much more effective than zoptarelin doxorubicin  [&lt;ulink linkID="467939" linkType="reference"&gt;467939&lt;/ulink&gt;]. By 1999, AEZS-108 showed high-affinity binding, was minimally toxic and inhibited tumor growth in vivo in LHRH receptor-positive models of human hormone-dependent cancer [&lt;ulink linkID="467641" linkType="reference"&gt;467641&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Zoptarelin doxorubicin  is administered intravenously after being kept in vials containing lyophilisate powder and being reconstituted with water [&lt;ulink linkID="651260" linkType="Reference"&gt;651260&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, Aeterna Zentaris and &lt;ulink linkID="1002756" linkType="Company"&gt;Ventana Medical Systems&lt;/ulink&gt; agreed to develop a companion diagnostic for the immunohistochemical determination of LHRH receptor expression for use with zoptarelin doxorubicin  8 [&lt;ulink linkID="1252656" linkType="Reference"&gt;1252656&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2002, Zentaris exclusively licensed worldwide rights for the development, manufacture and marketing of three cytotoxic compounds, zoptarelin doxorubicin, &lt;ulink linkID="20341" linkType="Drug"&gt;AN-238&lt;/ulink&gt; and &lt;ulink linkID="42225" linkType="Drug"&gt;AN-215&lt;/ulink&gt;, for the treatment of cancer from  Tulane University [&lt;ulink linkID="466729" linkType="reference"&gt;466729&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1075034">Sinopharma A-Think Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1771">Transitional cell carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="DOL1000087">Orient Europharma</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26232">Rafa Laboratories Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1075034">Sinopharma A-Think Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2017-05-01T00:00:00.000Z</StatusDate><Source id="1922888" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="42">Bladder tumor</Indication><StatusDate>2015-06-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22292">Tulane University</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2002-10-14T00:00:00.000Z</StatusDate><Source id="466729" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22292">Tulane University</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-10-14T00:00:00.000Z</StatusDate><Source id="466729" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22292">Tulane University</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2002-10-14T00:00:00.000Z</StatusDate><Source id="466729" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2005-01-18T00:00:00.000Z</StatusDate><Source id="580301" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2007-12-06T00:00:00.000Z</StatusDate><Source id="862616" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22292">Tulane University</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>1997-11-30T00:00:00.000Z</StatusDate><Source id="467946" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22292">Tulane University</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>1997-12-03T00:00:00.000Z</StatusDate><Source id="467945" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22292">Tulane University</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1999-01-01T00:00:00.000Z</StatusDate><Source id="467641" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="42">Bladder tumor</Indication><StatusDate>2010-12-14T00:00:00.000Z</StatusDate><Source id="1156094" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1771">Transitional cell carcinoma</Indication><StatusDate>2014-05-14T00:00:00.000Z</StatusDate><Source id="1571085" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2012-01-05T00:00:00.000Z</StatusDate><Source id="1252656" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1385088" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2007-12-06T00:00:00.000Z</StatusDate><Source id="862616" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2010-12-14T00:00:00.000Z</StatusDate><Source id="1156094" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2012-12-28T00:00:00.000Z</StatusDate><Source id="1353108" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2007-12-06T00:00:00.000Z</StatusDate><Source id="862616" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2007-12-06T00:00:00.000Z</StatusDate><Source id="862616" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2014-02-04T00:00:00.000Z</StatusDate><Source id="1521166" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2013-05-30T00:00:00.000Z</StatusDate><Source id="1401810" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2013-04-10T00:00:00.000Z</StatusDate><Source id="1402571" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2013-07-25T00:00:00.000Z</StatusDate><Source id="1401810" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2016-10-12T00:00:00.000Z</StatusDate><Source id="1806529" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1075034">Sinopharma A-Think Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2014-12-01T00:00:00.000Z</StatusDate><Source id="1616861" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2016-10-12T00:00:00.000Z</StatusDate><Source id="1806529" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="DOL1000087">Orient Europharma</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2016-07-01T00:00:00.000Z</StatusDate><Source id="1777630" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26232">Rafa Laboratories Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2016-08-01T00:00:00.000Z</StatusDate><Source id="1784622" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1075034">Sinopharma A-Think Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2014-12-01T00:00:00.000Z</StatusDate><Source id="1616861" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29069">Zentaris GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-10-16T00:00:00.000Z</StatusDate><Source id="466729" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-12-30T00:00:00.000Z</StatusDate><Source id="475158" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2005-01-18T00:00:00.000Z</StatusDate><Source id="580301" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2005-01-18T00:00:00.000Z</StatusDate><Source id="580301" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="42">Bladder tumor</Indication><StatusDate>2010-05-12T00:00:00.000Z</StatusDate><Source id="1098738" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22711">AEterna Zentaris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2009-06-01T00:00:00.000Z</StatusDate><Source id="1014425" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="22711">AEterna Zentaris Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-08-04T00:00:00.000Z</MileStoneDate><Source id="1222493" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="22711">AEterna Zentaris Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2010-05-06T00:00:00.000Z</MileStoneDate><Source id="1100071" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="22711">AEterna Zentaris Inc</OwnerCompany><Country id="US">US</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-04-30T00:00:00.000Z</MileStoneDate><Source id="1096462" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00881"><Name>GNRH receptor</Name><SwissprotNumbers><Swissprot>O18821</Swissprot><Swissprot>O42329</Swissprot><Swissprot>P30968</Swissprot><Swissprot>P30969</Swissprot><Swissprot>P32236</Swissprot><Swissprot>P32237</Swissprot><Swissprot>P49922</Swissprot><Swissprot>Q01776</Swissprot><Swissprot>Q8CH60</Swissprot><Swissprot>Q8SPZ1</Swissprot><Swissprot>Q95JG1</Swissprot><Swissprot>Q95MG6</Swissprot><Swissprot>Q95MH6</Swissprot><Swissprot>Q96P88</Swissprot><Swissprot>Q9MZI6</Swissprot><Swissprot>Q9TTI8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1015980">Shanghai Shyndec Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1021861">Ergomed PLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1026177">Almac Group</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1041584">Norris Comprehensive Cancer Center</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22292">Tulane University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22711">AEterna Zentaris Inc</Company><CountAsPrincipalActive>7</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>7</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>11</CountTotal></Company><Company><Company id="23577">Imperial College London</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="26232">Rafa Laboratories Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000087">Orient Europharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>5</CountActive><CountInactive>0</CountInactive><CountTotal>5</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)O</Smiles><Smiles>C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)NCC(=O)N)NC(=O)[C@H](Cc7ccc(cc7)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)O)N)O</Smiles><Smiles>C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)NCC(=O)N)NC(=O)[C@H](Cc7ccc(cc7)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)O)N)O.CC(=O)O</Smiles></StructureSmiles><Deals><Deal id="122598" title="Zentaris to develop Tulane University's cancer treatments"/><Deal id="131027" title="Almac Diagnostics to develop a companion diagnostic to Aeterna Zentaris's AEZS-108"/><Deal id="131414" title="NIH to award Norris Comprehensive Cancer Center funding to conduct phase I/II clinical trial of AEZS-108 "/><Deal id="131415" title="Norris Comprehensive Cancer Center to conduct phase I/II studies for AEterna Zentaris's AEZS-108"/><Deal id="137575" title="Ventana Medical Systems to develop a companion diagnostic test for Aeterna Zentaris to identify patients for AEZS-108 treatment  "/><Deal id="144738" title="Ergomed to conduct phase III clinical trial of AEterna Zentaris' AEZS-108 for endometrial cancer        "/><Deal id="146303" title="University of Texas Southwestern Medical Center to conduct phase III study for AEterna Zentaris' AEZS-108 against endometrial cancer"/><Deal id="146304" title="Imperial College London to conduct phase III study for AEterna Zentaris' AEZS-108 against endometrial cancer"/><Deal id="151905" title="Sinopharma to develop and commercialize AEterna Zentaris' Zoptarelin Doxorubicin against endometrial cancer in China, Hong Kong and Macau     "/><Deal id="161249" title="Cyntec to develop and commercialize Aeterna's Zoptrex against endometrial cancer in Taiwan and nine countries in Southeast Asia "/><Deal id="161738" title="Rafa Laboratories to develop and commercialize AEterna Zentaris' Zoptrex against endometrial cancer in Israel and the Palestinian                         "/><Deal id="162772" title="STA to develop and commercialize Aeterna's Zoptrex for cancer in Australia and New Zealand     "/></Deals><PatentFamilies><PatentFamily id="2053036" number="WO-09719954" title="Targeted cytotoxic anthracycline analogs."/><PatentFamily id="3207723" number="WO-2016116335" title="Enzymatic process for the regioselective manufacturing of n-fmoc-doxorubicin-14-o-dicarboxylic acid mono esters"/><PatentFamily id="3322601" number="CN-105859835" title="A preparation method of synthesis peptide-doxorubicin drug composition impurities"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Shyndec Pharmaceutical Co Ltd" id="1015980"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ergomed PLC" id="1021861"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Evonik Industries AG" id="1036094"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tulane University" id="22292"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AEterna Zentaris Inc" id="22711"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>